Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saccharomyces boulardii (Alde Medi Impex)
- Development stage
- Unknown
- Lead developer
- Alde Medi Impex
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Florill is a probiotic brand developed and marketed by Alde Medi Impex, primarily formulated with the beneficial yeast *Saccharomyces boulardii* (available in sachet and capsule forms) or the spore-forming bacterium *Bacillus clausii* (available as an oral suspension). It is approved and used for the prevention and treatment of various gastrointestinal disorders, including acute infectious diarrhea, antibiotic-associated diarrhea, colitis, and irritable bowel syndrome (IBS). Florill works by restoring and maintaining the natural balance of the intestinal microflora, competitively inhibiting the growth of pathogenic microorganisms, neutralizing bacterial toxins, and modulating local immune responses to strengthen the intestinal mucosal barrier.
- Brand names
- FlorillFlorill CapsulesFlorill Oral PowderFlorill Oral SuspensionFlorill SachetFlorill Suspension
- Other names
- Saccharomyces boulardii
02
Targets
αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)CLEC6A (C-type lectin domain family 6 member A)TLR (Toll-like receptors)
Beyond the preview
Go deeper on saccharomyces boulardii (Alde Medi Impex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saccharomyces boulardii (Alde Medi Impex).